This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In 2019, a team at Massachusetts Institute of Technology (MIT) in the US came up with just such a model, and found that it was able to perform “better than random” at predicting the outcome of a clinical trial or development programme.
Drugdevelopment is already a difficult endeavor, with the vast majority of R&D efforts failing to produce a market-worthy product. Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S. While this process is essential, it’s also slow, expensive and unpredictable.
The university and Pharos have drawn up a memorandum of understanding (MoU) to use AI technology to identify potential compounds for the rapid development of treatments. The MoU allows Pharos to collaborate with the university’s researchers and gives access to its advanced drug discovery infrastructure.
Many practitioners have expressed the feeling that EHRs cause far too much of their time ultimately being spent on dataentry. This comes from a variety of issues linked to these systems, but there is a big one of note. Finally, there is now a compelling reason for blockchain’s implementation in life sciences, here’s why.
As the amount and types of data expand exponentially, this problem only intensifies. Yet, ironically, that very growth in data sources may be one reason solutions have been slow to take hold. Clearing redundant data then becomes difficult, and programming complex edit checks becomes impossible.
Iddo Peleg (CEO, and one of the four co-founders of YonaLink) and Gav Martell (co-founder and vice president of business development) discussed how a recent $6 million funding round led by Debiopharm Innovation Fund will support their mission to transform clinical trials and bring lifesaving therapies to market faster.
Data integrity is the term used to describe the accuracy, consistency and reliability of data throughout its lifecycle. In the pharmaceutical/life sciences industries, maintaining data integrity is crucial given its role in making critical decisions that shape outcomes from drugdevelopment to human health.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content